Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DT-DEC01 in Duchenne Muscular Dystrophy
2024-519004-27-00Phase 2Authorised
- Sponsor
- Dystrogen Therapeutics
- Start
- Dec 2024
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of DT-DEC01 in Duchenne muscular dystrophy (DMD), sponsored by Dystrogen Therapeutics. Primary endpoints: Incidence and severity of adverse events, Change from baseline in functional assessments (Phase 1) and 4 more. Planned start Dec 2024; status: authorised.
02
Drugs
DT-DEC01
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on 2024-519004-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519004-27-00.